[ad_1]
- The collaboration will evaluate the safety and efficacy of Tessa's shielded human papillomavirus-specific T-cell (HPV) treatment combined with Merck's KEYTRUDA.® (pembrolizumab) to treat the limited number of effective treatment options for metastatic or recurrent cervical cancer
SINGAPORE, April 15, 2019 / PRNewswire / – Tessa Therapeutic, a clinical immunotherapy company specializing in autologous and standard allogeneic therapies targeting solid tumors, announced today that it has signed an agreement with Merck (known as MSD outside the United States). Canada), through a subsidiary, to evaluate the T-cell-specific treatment of Tessa's human armored papillomavirus, or TT12, in badociation with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 (programmed death-1) treatment, in patients with recurrent or metastatic cervical cancer with HPV 16 and 18 positive.
Under this agreement, Tessa will organize a multi-center phase. 1b/ 2 test to evaluate the safety and effectiveness of the badociation. The test is planned for an initiation into United States, Singapore and South Korea.
"We are very excited to be working with Merck to evaluate the potential of KEYTRUDA® in combination with Tessa's VST therapy for cervical cancer ", said Mr. Andrew Khoo, CEO and co-founder of Tessa Therapeutics. "Cervical cancer is a leading cause of death in women, particularly in some of the most vulnerable regions of the world, and the prognosis and current treatment options for patients with cancer. Metastatic uterine cervix are mediocre.We look forward to developing this new combination, which could bring more effective treatment options for these patients. "
Tessa's TT12 is an autologous cell therapy product composed of HPVSTs formed to target HPV 16/18 antigens and genetically engineered with a TGF-β decoy receptor to defeat the suppressive tumor microenvironment. The safety and choice of the optimal dose of screened HPVST in combination with another anti-PD-1 antibody is being evaluated in a separate, ongoing Phase 1 study sponsored by an investigator. United States, in patients with relapsing HPV-related cancers. Preliminary results from this trial show that shielded HPVST and its combination with anti-PD-1 are well tolerated, exhibit minimal toxicity and early signs of efficacy.
Dr. Ivan D. Horak, M.D., Tessa Therapeutics President of Research and Development "Tessa's study on Phase 1 of Phase 1 of Tessa has shown encouraging results, confirming the effectiveness of shielded HPVSTs in targeting HPV-positive tumors and the addition of ## STR1 ## 39; anti-PD-1 could suppress the potential immune inhibition that may hinder the destructive activity of HPVST tumors Bring this therapy into a phase 1b/ 2 clinical trial and the extension of clinical sites into Asia reflects our commitment to providing new therapies to more cancer patients around the world, as well as our belief that therapy can potentially improve the clinical outcomes of patients with advanced HPV-positive tumors. "
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., UNITED STATES.
Aon cervical cancer and shielded HPVST immunotherapy
According to the World Health Organization, cervical cancer is the fourth most important cancer in women worldwide and the second most important in less developed regions. Cervical cancer is caused by a badually acquired infection of some types of human papillomavirus (HPV), with two types of HPV (16 and 18) accounting for 70% of cervical cancers and precancerous cervical lesions.
Various studies have reported poor results in patients with metastatic cervical cancer. Currently, the median survival time for metastatic cervical cancer is only 8 to 13 months.[1] and the 5-year survival rate is 16.5% compared to 91.5% for localized cervical cancer[2]. Unlike patients with early-stage cervical cancer and locally advanced cervical cancer who have access to conventional treatments such as surgery, chemotherapy or radiation therapy, patients with Metastatic cervical cancer do not benefit from any standard treatment because of its heterogeneous manifestations.
T cells are an essential part of the body's immune system and play a central role in the fight against viral infections and cancers. Virus-specific T cells (VST), in particular, have the ability to recognize and kill infected cells while activating other parts of the immune system for a coordinated response.
HPVSTs are produced by collecting the patient's blood and selectively developing T cells that recognize HPV 16/18 antigens. To increase durability in the tumor microenvironment, HPVSTs are screened by modifying the cells so that they express a TGF-β lure receptor. Armored HPVSTs are developed before being subjected to strict quality control before being reinjected into the patient.
|
[1] van Meir H., Kenter GG, Burggraaf J., JR Kroep, J. Welters, CJ Melief, et al. The need to improve the treatment of advanced and metastatic cervical cancer, the reason for being chemo-immunotherapy combined. Anti-cancer agents Med Chem. 2014; 14: 190-203. [2] Shen G, Zhou H, Jia Z, Deng H. Diagnostic performance of diffusion-weighted MRI for the detection of pelvic metastatic lymph nodes in patients with cervical cancer: a systematic review and meta-badysis. Br J Radiol. 2015; 88: 20150063. |
About Tessa Therapeutics
Tessa Therapeutics is a clinical-stage immunotherapy company focused on the development of autologous, ready-to-use allogeneic therapies targeting solid tumors. Tessa's Virus-Specific T Cell Platform (VST) harnesses the body's potent anti-viral immune response and has proven successful in the treatment of solid tumors.
Tessa is building a portfolio of innovative new generation therapies by combining the qualities of VST with other immuno-oncology technologies. This includes a rapidly growing portfolio of clinical and preclinical autologous programs that target a wide range of cancers, including nasopharyngeal carcinoma, cervical cancer, oropharyngeal cancer, lung cancer, cancer bad, bladder cancer and cancer of the head and neck. In addition, Tessa uses her platform to develop an allogeneic treatment to treat Epstein-Barr virus-badociated lymphomas.
Tessa has developed robust operational and supply chain capabilities to successfully deliver T-cell therapy treatments to a large number of patients around the world. In collaboration with its academic, clinical and commercial research partners, Tessa has created a fully integrated approach to cancer treatment through immunotherapy.
For more information on Tessa, visit www.tessatherapeutics.com.
Tessa Therapeutics Media Contacts
Gladys Wong
[email protected]
+65 6384 0755
Brunswick Group
Will Carnwath, Ben Fry
[email protected]
+65 6426 8188
SOURCE Tessa Therapeutics
Related Links
http://www.tessatherapeutics.com
Source link
